Becton Dickinson & Co
Becton Dickinson & Co (BDX) is listed on NYSE and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Franklin Lakes, United States and has 72,000 employees. The company is worth $54.59B and trades at 46.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $21.84B in fiscal 2025, up 8.2% from the year before. Net income was $1.68B. The share price is within 3% of its 52-week high. It pays a dividend yielding 2.10%, and has raised its annual dividend for 28 years in a row in our records. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $98.07M. In that quarter, 1 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $13.96K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +5.4% over 5Y.
today you would have $1,141.45▲ +14.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $152.57 | $178.36 | $191.69 | $199.92 | $192.88 | $191.92 | $208.60 | $172.82 | $164.18 | $126.97 | $118.19 | $106.73 | $84.74 | $59.97 | $57.31 | $64.83 | $60.48 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 16.5% a year plus a 2.1% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 34.6 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividend growing 5.5% a year against a 7.0% required return, from the stock’s beta.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ARGXArgenx SE | $875.76 | 34.0x | 7.4x | 0.00% | 23.64% | $55.07B |
| VEEVVeeva Systems Inc | $322.55 | 52.5x | 7.0x | 0.00% | 14.43% | $52.22B |
| EWEdwards Lifesciences Corp | $90.09 | 53.6x | 4.9x | 0.00% | 9.18% | $51.93B |
| NTRANatera, Inc. | $401.37 |
| $52.45 |
| $64.10 |
| P/E | 34.6x | 33.3x | 38.7x | 49.4x | 43.2x | 35.8x | 90.1x | 69.0x | 375.5x | 46.5x | 36.9x | 46.0x | 23.2x | 17.0x | 14.0x | 13.3x | 15.4x | 15.8x | 15.3x | 23.9x |
| P/S | 3.2x | 2.5x | 3.3x | 3.7x | 3.8x | 3.7x | 4.5x | 4.3x | 3.8x | 4.0x | 2.8x | 3.2x | 3.2x | 2.7x | 2.0x | 2.1x | 2.7x | 2.7x | 2.5x | — |
| P/B | 3.5x | 2.2x | 2.5x | 2.7x | 2.9x | 3.0x | 3.1x | 3.5x | 2.9x | 3.8x | 4.6x | 4.5x | 5.3x | 4.3x | 3.7x | 3.3x | 3.6x | 3.6x | 3.5x | — |
| EPS | $4.58 | $4.61 | $3.88 | $4.62 | $5.39 | $2.13 | $3.02 | $0.46 | $3.53 | $3.44 | $2.57 | $4.59 | $4.98 | $4.29 | $4.31 | $4.21 | $3.83 | $3.42 | $2.68 |
| Dividend yield | 1.61% | 2.15% | 1.71% | 1.51% | 1.38% | 1.34% | 1.28% | 1.14% | 1.34% | 1.37% | 1.64% | 1.60% | 1.61% | 1.84% | 2.36% | 2.25% | 1.80% | 1.72% | 1.73% | 1.22% |
| Payout | 59.50% | 71.65% | 66.38% | 74.49% | 59.50% | 47.85% | 115.20% | 78.68% | 503.33% | 63.91% | 60.36% | 73.43% | 37.31% | 31.28% | 33.01% | 29.89% | 27.69% | 27.25% | 26.57% | 29.23% |
| Profit margin | 9.43% | 7.68% | 8.45% | 7.66% | 9.43% | 10.94% | 5.44% | 7.13% | 1.95% | 9.10% | 7.82% | 6.76% | 14.03% | 16.05% | 15.18% | 16.76% | 18.49% | 17.63% | 16.34% | 14.17% |
| ROE | 9.27% | 6.61% | 6.59% | 5.75% | 7.04% | 8.84% | 3.68% | 5.85% | 1.48% | 8.50% | 12.79% | 9.70% | 23.45% | 25.64% | 28.29% | 26.32% | 24.24% | 23.95% | 22.83% | — |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
7 methods answered, across 4 families.
Room for errors in the reported numbers.
-15.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 31.6x |
| 0.00% |
| -12.54% |
| $57.86B |
| HUMHumana Inc | $420.97 | 39.8x | 2.6x | 0.84% | 6.89% | $50.55B |
| CAHCardinal Health Inc | $255.64 | 35.4x | — | 0.81% | — | $59.2B |